Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies

Identifying effective immunotherapies for solid tumors remains challenging despite the significant clinical responses observed in subsets of patients treated with immune checkpoint inhibitors. Interleukin-15 (IL-15) is a promising cytokine for the treatment of cancer as it stimulates NK and CD8<s...

Full description

Bibliographic Details
Main Authors: Grace Lui, Christine M. Minnar, Patrick Soon-Shiong, Jeffrey Schlom, Sofia R. Gameiro
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/12/12/1611